My Ultimate Sign-in System Made Me Invincible-Chapter 464: Hands Are Tied (2)
The announcement hit London at a civilized hour and that almost made it worse.
There was no scrambling out of bed. No disoriented reading of something extraordinary on a phone screen in the dark. The people who needed to see it saw it at their desks, in their offices, in the kind of controlled professional environments where reactions were supposed to be managed before they became visible.
The management lasted approximately four minutes.
The first person to finish reading it in the Department of Health and Social Care sat very still for a moment. Then she picked up her phone and called her director. She didn’t say anything when he answered. She just read him all of the subscription tier prices, in order, slowly.
He told her he’d call her back, but he didn’t call her back for two hours.
By the time the senior health ministers were assembled the announcement had already been dissected, forwarded, screenshotted, and discussed by approximately forty million British citizens. Social media had done in forty minutes what conventional news cycles would have taken days to accomplish. The public wasn’t waiting for an official response. The public had already formed one.
The mood in the assembly room was the particular kind of quiet that settles over serious people when they realize the thing they’re looking at is larger than their existing frameworks can accommodate.
Someone had printed the announcement. Twelve pages. The stack sat in the center of the table and nobody touched it because everyone had already read it three times on their own devices before arriving.
The first question asked in that room was not about the science. It was not about regulatory jurisdiction. It was not about the geopolitical implications of a private company announcing off world medical trials.
It was simpler than all of that.
Someone asked what it meant for the NHS.
The silence that followed lasted long enough to become its own answer.
The NHS was the closest thing Britain had to a sacred institution. It had survived wars, privatization debates, funding crises, and decades of political warfare from every direction. It represented something beyond healthcare. It represented a collective promise that British society made to itself about what kind of country it wanted to be. You would be cared for. Regardless of your income. Regardless of your circumstances. The state would be there.
Nova Medical Nanites didn’t attack that promise. They made it look small.
Not because the NHS had failed. Because what Nova Technologies was describing operated at a level that no state institution, no matter how well funded or well intentioned, could have reached. A $99 monthly subscription that handled infectious disease and early stage illness detection. A $299 tier that eliminated cancer. The NHS had been fighting cancer with everything available to modern medicine for decades. Nova Technologies was offering to eliminate it for less than a monthly gym membership.
The person who had asked the question about the NHS looked around the table and said quietly that they needed to think very carefully about what they said publicly in the next forty eight hours. Because whatever they said would be measured against that pricing structure for years.
Everyone agreed. Nobody knew what to say instead.
The regulatory question arrived quickly and answered itself almost as fast.
Britain’s medicines regulator had jurisdiction over what could be approved for use in the United Kingdom. It had no jurisdiction over what happened on an off-world facility. The clinical trial Nova Technologies had announced was occurring in a location that no existing regulatory framework had been designed to address. There was no provision in British law for evaluating the approval status of a medical procedure conducted in orbit.
The legal team that delivered this assessment did so with the careful language of people accustomed to presenting uncomfortable conclusions professionally. They noted that British citizens were legally free to travel internationally to participate in medical trials. They noted that the trial’s off world location created a jurisdictional ambiguity that would require entirely new legislative frameworks to address. They noted that creating those frameworks would take considerably longer than ninety days.
What they did not note but everyone understood was that by the time any new regulatory framework was designed, debated, passed, and implemented the trial would had already started or would had already been over. Legislation aimed at a trial that had already concluded was not regulation. It was theatre.
One minister suggested they focus on what they could actually influence rather than what they couldn’t. The room agreed. The question then became whether sending official observers was an act of engagement that implied legitimacy or an act of scientific responsibility that implied nothing except a commitment to having firsthand information.
The debate on that distinction lasted longer than anyone was comfortable admitting afterward.
***
Brussels received the announcement at the same civilized hour and reacted with the particular complexity that came from being twenty seven different governments attempting to form a single coherent response to something none of them had a precedent for. 𝕗𝚛𝚎𝚎𝐰𝗲𝗯𝗻𝚘𝚟𝚎𝗹.𝕔𝐨𝕞
The initial calls between health ministers across member states produced a map of competing instincts that reflected the diversity of the union itself. Countries whose healthcare systems were already under pressure from aging populations and underfunding saw the nanite announcement through a lens of desperate hope mixed with profound anxiety about access. Countries with strong domestic pharmaceutical industries saw it through a lens of economic threat. Countries with strong scientific research traditions saw it through a lens of extraordinary opportunity. Countries with strong sovereignty concerns saw it through a lens of institutional alarm.
Getting twenty seven of those lenses to produce a single focused image in under ninety days was the challenge.
The European Medicines Agency found itself in a position it had never occupied before. Its mandate was the evaluation and approval of medicines and medical devices for use within the European Union. Nova Medical Nanites were described in the announcement as neither a medicine nor a medical device. They were precision medical infrastructure. That distinction was not semantic. It was a structural argument that the existing approval framework had no category for what was being described.
An internal assessment concluded that evaluating Nova Medical Nanites under existing EMA frameworks would be approximately equivalent to evaluating a space shuttle under the regulations governing bicycles. The frameworks weren’t wrong. They simply weren’t designed for what they were being asked to assess.
This conclusion was delivered to health ministers across member states with the recommendation that the EU needed to develop entirely new evaluation frameworks before any meaningful regulatory engagement with the technology was possible.
Several ministers asked how long that would take, and the answer was not received well.
The public pressure in Europe arrived differently than it did in Britain. In Britain it came quickly and loudly through social media and direct citizen communication to representatives. In Europe it came through the particular channels that European civic life had developed over decades. Patient advocacy organizations. Medical research foundations. Disability rights groups. Organizations representing people living with the specific conditions named in Nova Technologies’ announcement.
These organizations didn’t wait for government responses. They issued their own statements within twenty four hours. The language was measured where it needed to be measured and unambiguous where it needed to be unambiguous.
One statement from a pan-European cancer patient advocacy organization noted that the announcement described the elimination of all known forms of cancer. It asked member state governments to consider what their response to that claim said about their priorities. It did not tell governments what to do. It didn’t need to. The implication was clear enough to survive translation into twenty three official languages without losing any of its force.
Neurological disease foundations published similar statements. Autoimmune disorder organizations. Rare disease communities whose members had spent years navigating healthcare systems that could manage their conditions but not resolve them. Each statement came from a different constituency and landed on the same point from a different angle.
The governments of Europe were being asked to respond to something that directly affected the lives of millions of their citizens. The nature of that response would be remembered.
The debate inside EU institutions about whether to send observers produced arguments that were genuinely difficult to resolve cleanly.
The case against participation rested on institutional credibility. Sending observers to a trial occurring outside any regulatory jurisdiction, conducted by a company that had explicitly stated it would not submit to regulatory control as a condition of any approval process, could be interpreted as implicit legitimacy. The EU’s regulatory authority derived partly from its consistency. Being seen to engage with processes that operated entirely outside its framework raised questions about where the boundaries of that framework actually were.
The case for participation was simpler and ultimately harder to dismiss.
The technology was real. The trial was happening regardless of European participation. Citizens of EU member states were going to be affected by whatever this technology turned out to be. Having no firsthand information, no independent verification, no official European presence in the room when history was being made was a failure of institutional responsibility that no argument about regulatory credibility could justify.
A senior figure in the health policy architecture of the EU put it simply during one of the later discussions. She said that institutions existed to serve people. The people of Europe had a direct and urgent interest in what Nova Technologies had announced. An institution that prioritized its own procedural dignity over the interests of the people it served had confused its purpose with its existence.
The room didn’t respond immediately.
Then someone said that was probably the most accurate thing said in any of these meetings and they should probably vote before anyone thought of a counterargument.
**"
Both Britain and the EU arrived at the same destination through different routes and at different speeds.
They would send observers.
Not because Nova Technologies needed them to. Not because it changed anything about the trial or the timeline or the terms Nova Technologies had already set. But because the alternative was watching from the outside while something that would reshape their societies happened without them in the room.
The statements confirming participation were written and rewritten many times before release. Every word was evaluated for what it implied about regulatory recognition, institutional endorsement, and political positioning.
The final versions said as little as possible while confirming as much as necessary.
